Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Fulcrum Therapeutics Q2 EPS Totals $0.87 Compared With $(0.38) Loss YoY, Company Exits Quarter With Cash And Equivalents Worth $273.8M

Author: Benzinga Newsdesk | July 31, 2024 07:08am

Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly earnings of $0.87 per share his is a 328.95 percent increase over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $80.00 thousand which missed the analyst consensus estimate of $27.66 million by 99.71 percent. This is a 90.91 percent decrease over sales of $880.00 thousand the same period last year.

Posted In: FULC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist